Table 1.
Baseline characteristics in the first-line switch-maintenance and second-line subgroups
| Characteristics | 1 L-mn subgroup (n = 90) | 2 L subgroup (n = 60) |
|---|---|---|
| Median age (IQR), years | 59 (52.0–67.0) | 62.5 (51.5–66.0) |
| Sex, n (%) | ||
| Male | 68 (75.6) | 46 (76.7) |
| Female | 22 (24.4) | 14 (23.3) |
| ECOG PS, n (%) | ||
| 0 | 37 (41.1) | 23 (38.3) |
| 1 | 53 (58.9) | 37 (61.7) |
| Geographic region, n (%) | ||
| North America | 31 (34.4) | 32 (53.3) |
| Asia | 34 (37.8) | 10 (16.7) |
| Europe | 25 (27.8) | 18 (30.0) |
| Race, n (%) | ||
| White | 44 (48.9) | 36 (60.0) |
| Asian | 35 (38.9) | 13 (21.7) |
| Black | 4 (4.4) | 4 (6.7) |
| Other | 7 (7.8) | 7 (11.7) |
| Histology, n (%) | ||
| Tubular | 18 (20.0) | 3 (5.0) |
| Signet ring | 17 (18.9) | 13 (21.7) |
| Mucinous | 4 (4.4) | 4 (6.7) |
| Papillary | 1 (1.1) | 0 |
| Other/not specified | 1 (1.1) | 0 |
| Unknown | 37 (41.1) | 39 (65.0) |
| PD-L1 expression status based on ≥1% cutoff on tumor cells, n (%) | ||
| PD-L1+ | 26 (28.9) | 20 (33.3) |
| PD-L1− | 51 (56.7) | 25 (41.7) |
| Not evaluable | 13 (14.4) | 15 (25.0) |
| HER2 status, n (%) | ||
| HER2− | 62 (68.9) | 29 (48.3) |
| HER2+ | 4 (4.4) | 5 (8.3) |
| Unknown | 24 (26.7) | 26 (43.3) |
| Microsatellite status, n (%) | ||
| Low | 1 (1.1) | 0 |
| Stable | 21 (23.3) | 17 (28.3) |
| High | 2 (2.2) | 2 (3.3) |
| Unknown | 66 (73.3) | 41 (68.3) |
| Prior gastrectomy, n (%) | 24 (26.7) | 14 (23.3) |
| Metastatic disease status at study entry, n (%) | ||
| M0 | 5 (5.6) | 2 (3.3) |
| M1 | 85 (94.4) | 58 (96.7) |
| Tumor size at baselinea | ||
| Median (IQR), mm | 33 (19–52) | 44 (25–69.5) |
| Unknown, n (%) | 1 (1.1) | 1 (1.7) |
| Best response to prior anticancer therapy, n (%) | ||
| Complete response | 0 | 1 (1.7) |
| Partial response | 25 (27.8) | 8 (13.3) |
| Stable disease | 59 (65.6) | 23 (38.3) |
| Progressive disease | 0 | 22 (36.7) |
| Not evaluable or unknown | 6 (6.7) | 5 (8.3) |
| Prior anticancer therapy (any setting), n (%) | 90 (100) | 60 (100) |
| Number of prior lines of anticancer therapy for metastatic or locally advanced disease, n (%) | ||
| 0 | 1 (1.1) | 5 (8.3) |
| 1 | 87 (96.7) | 53 (88.3) |
| 2 | 2 (2.2) | 1 (1.7) |
| Unknown | 0 | 1 (1.7) |
| Median prior lines (range) | 1.0 (0–2) | 1.0 (0–2) |
| Interval from end of prior chemotherapy to start of avelumab therapy | ||
| Median (IQR), days | 45 (35–64) | 77 (49–135) |
| Data missing, n (%) | 8 (8.9) | 15 (25.0) |
aSum of the longest diameters of target lesions
Abbreviations: 1 L-mn first-line switch-maintenance, 2 L second line, ECOG PS Eastern Cooperative Oncology Group performance status, IQR interquartile range